Outcomes of Pediatric Patients with Crohn’s Disease Received Infliximab or Exclusive Enteral Nutrition during Induction Remission

Table 2

Demographic and clinical characteristics of enrolled patients at the beginning of maintenance therapy.

	IFX+IFX	EEN+6-MP/MTX	value
	14	10
Age (yr)	(11.17-15.58)	(8.75-15.75)	0.32
Males/females	13/1	8/2	0.55
Height (cm)			0.42
Weight (kg)			0.22
HFA -score			0.56
BMIFA -score			0.24
PCDAI score			0.40
CDEIS score			0.44
Disease location, (%)			0.21
L1	9.4	6.3
L2	0	0
L3	28.1	50
L4a	28.1	6.3
L4b	34.4	37.5
Disease behavior, (%)			0.48
B1	81.8	100
B2	18.2	0
Perianal disease, (%)	71.4	0	0.00
Disease growth, (%)			1.00
G0	85.7	80
G1	14.3	20
Alb (g/L)			0.91
ESR (mm/h)			0.12
CRP (mg/L), normal (%)	100	100
Maintenance therapy (%)			0.00
IFX	100	0
6-MP/MTX	0	100
Used PEN during the maintenance therapy	No	No	>0.05

IFX: infliximab; EEN: exclusive enteral nutrition; PCDAI: pediatric Crohn’s disease activity index; CDEIS: Crohn’s disease endoscopic index of severity; BMIFA: body mass index for age; HFA: height for age; Alb: albumin; ESR: erythrocyte sedimentation rate; CRP: C reactive protein; 6-MP: 6-mercaptopurine; MTX: methotrexate; PEN: partial enteral nutrition.